Cogent BiosciencesCOGT
About: Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Employees: 205
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
60% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 20
32% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 50
7.05% more ownership
Funds ownership: 110.19% [Q4 2024] → 117.24% (+7.05%) [Q1 2025]
5% more funds holding
Funds holding: 175 [Q4 2024] → 184 (+9) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 8 [Q4 2024] → 8 (+0) [Q1 2025]
16% less capital invested
Capital invested by funds: $949M [Q4 2024] → $800M (-$150M) [Q1 2025]
75% less call options, than puts
Call options by funds: $355K | Put options by funds: $1.42M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
JP Morgan Anupam Rama | 253%upside $25 | Overweight Maintained | 29 May 2025 |
HC Wainwright & Co. Robert Burns | 69%upside $12 | Buy Maintained | 20 May 2025 |
Baird Joel Beatty | 1%downside $7 | Neutral Maintained | 7 May 2025 |
Financial journalist opinion
